Literature DB >> 23227738

[Early rethoracotomies for diseases and chest traumas].

S A Plaksin, M E Petrov.   

Abstract

Rethoracotomies were performed on 34 patients operated for diseases and traumas of the chest, diseases of the esophagus which made up 1.3%. Emergency and reoperations were performed on 14 (46%) patients for ongoing intrapleural bleeding, clotted hemothorax and pulmonary bleeding. Emergency and delayed rethoracotomies were performed on 7 patients for non-hermeticity of the lung and incompetence of the bronchus suture, on 5 patients for incompetence of esophagogastroanastomosis, necrosis of the transplant and gastric wall, 3 patients for chylothorax not-arrested conservatively, 2 patients for gangrene of the residual lung lobe due to disturbed venous outflow. Postoperative complications resulted in death of 12 (37.5%) patients. Causes of lethal outcomes were purulent complications (pleural empyema, mediastinitis, sepsis, polyorganic insufficiency--in 5), massive blood loss with the development of coagulopathy (in 4), pneumonia of the only lung after pulmonectomy (in 2), pulmonary embolism (in 1). In addition, torsion of the residual lung lobe, foreign body in the pleural cavity can be considered as indications for rethoracotomy.

Entities:  

Mesh:

Year:  2012        PMID: 23227738

Source DB:  PubMed          Journal:  Vestn Khir Im I I Grek        ISSN: 0042-4625


  2 in total

1.  Early reoperation performed for the management of complications in patients undergoing general thoracic surgical procedures.

Authors:  Christophoros N Foroulis; Athanasios Kleontas; Avgerinos Karatzopoulos; Chryssoula Nana; George Tagarakis; Paschalis Tossios; Paul Zarogoulidis; Kyriakos Anastasiadis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

2.  Rethoracotomy for early complications: A marker for increased morbidity and mortality.

Authors:  Serkan Yazgan; Ahmet Üçvet; Soner Gürsoy; Özgür Samancılar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.